Advances in the Diagnosis and Interventional Management of Peripheral Artery Disease: Emerging Technologies, Evidence, and Clinical Pathways

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 106

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland
Interests: peripheral artery disease; peripheral interventions; atherosclerosis; angioplasty

Special Issue Information

Dear Colleagues,

Peripheral artery disease (PAD) remains a major global cause of functional impairment, limb loss, and cardiovascular mortality. Despite progress in diagnostic imaging and endovascular therapies, significant gaps persist in early detection, lesion-specific assessment, and personalized treatment strategies. This Special Issue aims to provide an updated and comprehensive overview of contemporary PAD, focusing on innovative diagnostic tools, optimized interventional techniques, and evidence-based medical therapies. Topics of interest include advances in non-invasive testing, duplex and cross-sectional imaging, and the use of intravascular modalities for plaque characterization. Contributions addressing chronic total occlusions, calcified lesions, vessel preparation, drug-coated technologies, and comparative effectiveness between angioplasty strategies are particularly encouraged. We encourage submissions on antithrombotic management, risk factor optimization, and multidisciplinary approaches to chronic limb-threatening ischemia. Emerging areas such as artificial intelligence, computational modeling, digital health applications, and remote monitoring for PAD management are highly relevant.

This Special Issue aims to bring together high-quality original research and reviews to advance precision evaluation and treatment of PAD, and to define future directions in vascular medicine.

Dr. Ioannis Skalidis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peripheral artery disease
  • peripheral interventions
  • atherosclerosis
  • angioplasty
  • diagnosis and treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 783 KB  
Article
Comparative Effectiveness of Peripheral Angioplasty Strategies for 1-Year Restenosis in Lower Limb Artery Disease: A Retrospective Single-Center Analysis
by Ioannis Skalidis, Livio D’Angelo, Youcef Lounes, Francesca Sanguineti, Antoinette Neylon, Hakim Benamer, Benjamin Honton, Antoine Sauguet, Neila Sayah, Pietro Laforgia, Nicolas Amabile, Thomas Hovasse, Philippe Garot, Mariama Akodad, Stephane Champagne and Thierry Unterseeh
Biomedicines 2025, 13(12), 3100; https://doi.org/10.3390/biomedicines13123100 - 16 Dec 2025
Viewed by 69
Abstract
Background: Optimal endovascular strategy for lower limb peripheral artery disease (PAD) remains debated, particularly regarding 1-year restenosis. Aim: To evaluate the association between drug-coated balloon (DCB)-based angioplasty and 1-year restenosis compared with stent-based and plain balloon strategies in a real-world PAD cohort. Methods: [...] Read more.
Background: Optimal endovascular strategy for lower limb peripheral artery disease (PAD) remains debated, particularly regarding 1-year restenosis. Aim: To evaluate the association between drug-coated balloon (DCB)-based angioplasty and 1-year restenosis compared with stent-based and plain balloon strategies in a real-world PAD cohort. Methods: We performed a single-center retrospective analysis of 283 consecutive patients (mean age 67.5 ± 11.2 years, 79% male) undergoing lower limb angioplasty between 2010 and 2023. Patients were treated with one of five strategies: direct stent, pre-dilatation + stent, stent + post-dilatation, DCB ± bailout stent, or plain old balloon angioplasty (POBA). Restenosis at 12 months (≥50% diameter reduction on Doppler, CT angiography, or angiography) was the primary endpoint. Kaplan-Meier curves and multivariable Cox regression adjusted for clinical and lesion characteristics were used. The prespecified main comparison was DCB ± stent versus non-DCB strategies. Results: Overall, 1-year restenosis occurred in 81 patients (28.7%). Restenosis rates were 15.4% with DCB ± stent versus 34.2%, 29.8%, 31.5%, and 38.1% with direct stent, pre-dilatation + stent, stent + post-dilatation, and POBA, respectively (p = 0.004). In adjusted analysis, DCB ± stent was associated with a lower hazard of restenosis compared with direct stent (HR 0.52; 95% CI 0.31–0.87), whereas POBA was associated with a higher hazard versus DCB ± stent (HR 1.89; 95% CI 1.01–3.53). Periprocedural complication rates were low and similar across groups (overall 6.3%). Conclusions: In this real-world PAD cohort, DCB-based angioplasty was independently associated with lower 1-year restenosis compared with stent-based and plain balloon strategies, without an excess of procedural complications. Given the observational design and lesion-driven strategy selection, these findings should be interpreted as hypothesis-generating but support broader use of DCB in appropriately selected lesions. Full article
Show Figures

Figure 1

Back to TopTop